A specialty drug company called Revive Therapeutics Ltd reports that the U.S. Food & Drug Administration (FDA) has approved their bid to proceed with a Phase 3 clinical trial to evaluate Bucillamine’s safety and efficacy in patients with mild-to-moderate COVID-19....